Factors Associated with Clinical Response to Low-Dose Dexamethasone Therapy for Bronchopulmonary Dysplasia in Very Low Birth Weight Infants
5
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To identify factors associated with the clinical response to low-dose dexamethasone therapy (LDDT) in preterm infants for bronchopulmonary dysplasia (BPD). Methods: We used a retrospective medical record review to evaluate preterm infants who were born before 32 weeks of gestation or with a birth weight less than 1,500 g. All infants were admitted to the neonatal intensive care unit at a tertiary academic hospital between January 2010 and June 2019, and received LDDT for BPD. The preterm infants’ respiratory severity scores (RSS) were calculated from the first day of LDDT to the day of extubation, or the last day of LDDT. A good response was defined as a decreasing RSS with a slope greater than 0.181. A poor response was defined as a non-decreasing RSS, or a decreasing RSS with a slope less than 0.181 during LDDT. A total dose of 1.1 mg/kg was administered for 10 days for each single course of LDDT. Results: A total of 51 preterm infants were included in the final analysis. Thirty preterm infants (58.8 %) were in the good response group, and 21 preterm infants (41.2%) were in the poor response group. There were no significant differences in gestational age, birth weight, and sex between the good response group and poor response group. Preterm premature rupture of membrane and histologic chorioamnionitis were significantly associated with a poor response to LDDT. Higher RSS on the first day of the LDDT was associated with a good response to LDDT. Conclusion: Antenatal infection and/or inflammation may be associated with an unfavorable response to postnatal LDDT for BPD. Preterm infants with more severe respiratory failure seem to benefit more from LDDT for BPD.
Abstract
Purpose: To identify factors associated with the clinical response to low-dose dexamethasone therapy (LDDT) in preterm infants for bronchopulmonary dysplasia (BPD). Methods: We used a retrospective medical record review to evaluate preterm infants who were born before 32 weeks of gestation or with a birth weight less than 1,500 g. All infants were admitted to the neonatal intensive care unit at a tertiary academic hospital between January 2010 and June 2019, and received LDDT for BPD. The preterm infants’ respiratory severity scores (RSS) were calculated from the first day of LDDT to the day of extubation, or the last day of LDDT. A good response was defined as a decreasing RSS with a slope greater than 0.181. A poor response was defined as a non-decreasing RSS, or a decreasing RSS with a slope less than 0.181 during LDDT. A total dose of 1.1 mg/kg was administered for 10 days for each single course of LDDT. Results: A total of 51 preterm infants were included in the final analysis. Thirty preterm infants (58.8 %) were in the good response group, and 21 preterm infants (41.2%) were in the poor response group. There were no significant differences in gestational age, birth weight, and sex between the good response group and poor response group. Preterm premature rupture of membrane and histologic chorioamnionitis were significantly associated with a poor response to LDDT. Higher RSS on the first day of the LDDT was associated with a good response to LDDT. Conclusion: Antenatal infection and/or inflammation may be associated with an unfavorable response to postnatal LDDT for BPD. Preterm infants with more severe respiratory failure seem to benefit more from LDDT for BPD.
참고문헌 (37)
- Baraldi E, "Chronic lung disease after premature birth", N Engl J Med, 357, pp.1946~1955 (2007)
- Jo HS, "Recent changes in the incidence of bronchopulmonary dysplasia among very-lowbirth-weight infants in Korea", J Korean Med Sci, 30(Suppl 1), pp.S81~S87 (2015)
- 김진규, "Trends in Survival and Incidence of Bronchopulmonary Dysplasia in Extremely Preterm Infants at 23-26 Weeks Gestation", Journal of Korean Medical Science, 31(3), pp.423~429 (2016), 대한의학회
- Manktelow BN, "Factors affecting the incidence of chronic lung disease of prematurity in 1987, 1992, and 1997", Arch Dis Child Fetal Neonatal Ed, 85, pp.F33~F35 (2001)
- Stoll BJ, "Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012", JAMA, 314, pp.1039~1051 (2015)
- Doyle LW, "Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants", Cochrane Database Syst Rev, 5, pp.CD001146~ (2014)
- Lin YJ, "Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy", Pediatr Pulmonol, 27, pp.21~26 (1999)
- Olaloko O, "Evaluating the use of corticosteroids in preventing and treating bronchopulmonary dysplasia in preterm neonates", Int J Gen Med, 11, pp.265~274 (2018)
- Groneck P, "Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease", J Pediatr, 122, pp.938~944 (1993)
- Gupta S, "Postnatal corticosteroids for prevention and treatment of chronic lung disease in the preterm newborn", Int J Pediatr, 2012, pp.315642~ (2012)
- Ehrenkranz RA, "Effective care of the newborn infant", pp.399~424 (1992), Oxford University Press
- Shah SS, "Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates", Cochrane Database Syst Rev (2017)
- Onland W, "Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants", Cochrane Database Syst Rev, 1, pp.CD010941~ (2017)
- Michael Z, "Bronchopulmonary dysplasia : an update of current pharmacologic therapies and new approaches", Clin Med Insights Pediatr, 12, pp.1179556518817322~ (2018)
- Onland W, "Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial", JAMA, 321, pp.354~363 (2019)
- Morris IP, "Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis", Eur J Pediatr, 178, pp.1171~1184 (2019)
- Kalikkot Thekkeveedu R, "Bronchopulmonary dysplasia : a review of pathogenesis and pathophysiology", Respir Med, 132, pp.170~177 (2017)
- Gien J, "Pathogenesis and treatment of bronchopulmonary dysplasia", Curr Opin Pediatr, 23, pp.305~313 (2011)
- Salafia CM, "The prevalence and distribution of acute placental inflammation in uncomplicated term pregnancies", Obstet Gynecol, 73, pp.383~389 (1989)
- Fenton TR, "A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants", BMC Pediatr, 13, pp.59~ (2013)
- Bhandari V, "Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia", Birth Defects Res A Clin Mol Teratol, 100, pp.189~201 (2014)
- Thebaud B, "Bronchopulmonary dysplasia", Nat Rev Dis Primers, 5, pp.78~ (2019)
- Avery ME, "Is chronic lung disease in low birth weight infants preventable? A survey of eight centers", Pediatrics, 79, pp.26~30 (1987)
- Trembath A, "Predictors of bronchopulmonary dysplasia", Clin Perinatol, 39, pp.585~601 (2012)
- Doyle LW, "Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial", Pediatrics, 117, pp.75~83 (2006)
- Doyle LW, "Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants", Cochrane Database Syst Rev, 10, pp.CD001145~ (2017)
- Torchin H, "Placental complications and bronchopulmonary dysplasia : EPIPAGE-2 cohort study", Pediatrics, 137, pp.e20152163~ (2016)
- Bhatt AJ, "Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia", Am J Respir Crit Care Med, 164, pp.1971~1980 (2001)
- Speer CP, "Pulmonary inflammation and bronchopulmonary dysplasia", J Perinatol, 26(Suppl 1), pp.S57~S62 (2006)
- 최창원, "Chorioamnionitis: Is a major player in the development of bronchopulmonary dysplasia?", Clinical and Experimental Pediatrics, 60(7), pp.203~207 (2017), 대한소아청소년과학회
- Barrington KJ, "The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs", BMC Pediatr, 1, pp.1~ (2001)
- Halliday HL, "Delayed(>3 weeks)postnatal corticosteroids for chronic lung disease in preterm infants", Cochrane Database Syst Rev, 2, pp.CD001145~ (2001)
- Doyle LW, "Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia: who might benefit?", Semin Fetal Neonatal Med, 22, pp.290~295 (2017)
- Cheong JL, "Association between postnatal dexamethasone for treatment of bronchopulmonary dysplasia and brain volumes at adolescence in infants born very preterm", J Pediatr, 164, pp.737~743 (2014)
- Jobe AH, "Postnatal corticosteroids for bronchopulmonary dysplasia", Clin Perinatol, 36, pp.177~188 (2009)
- Zeng L, "Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis", Arch Dis Child Fetal Neonatal Ed, 103, pp.F506~F511 (2018)
- Cuna A, "Timing of postnatal corticosteroid treatment for bronchopulmonary dysplasia and its effect on outcomes", Pediatr Pulmonol, 54, pp.165~170 (2019)